Press Releases

DigitalBridge Group, Inc. (NYSE:DBRG) (the "Company") today announced two of its subsidiaries, DigitalBridge Issuer, LLC and DigitalBridge Co-Issuer, LLC (together, the "Co-Issuers") have priced an offering of $300 million aggregate principal amount of Series 2026-1 6.326% Secured Fund Fee Revenue Notes, Class A-2 (the "Class A-2 Notes"). Interest payments on the Class A-2 Notes are payable on a quarterly basis. The anticipated repayment date of the Class A-2 Notes is June 2031. The Class A-2 Notes are expected to be issued by the Co-Issuers in a securitization transaction. The proceeds from the sale of the Class A-2 Notes, net of the payment of certain offering expenses and the deposits

Participating shareholders to receive cash distribution of US$1.435518 per common shareShares to begin trading on a post-consolidated basis on May 4, 2026TORONTO, May 1, 2026 /CNW/ -- Thomson Reuters (TSX/Nasdaq: TRI) today announced the cash distribution per share and the share consolidation ratio for its return of capital and share consolidation transactions, which have received the requisite approvals and will be effective at 3:01 a.m. (Toronto time) on May 4, 2026. The company's common shares will begin trading on the Toronto Stock Exchange (TSX) and the Nasdaq on a post-consolidated basis when the markets open on May 4, 2026. The company's trading symbol will remain "TRI" on both exchan

Vancouver, British Columbia--(Newsfile Corp. - May 1, 2026) - Galiano Gold Inc. (TSX:GAU) (NYSE:GAU) ("Galiano" or the "Company") advises its Annual General and Special Meeting of shareholders ("AGM") will be held as a fully virtual meeting on Thursday, June 11, 2026, at 10:00 am PDT. Shareholders who intend to participate in the AGM should refer to the Company's Management Information Circular (the "Proxy Circular") for details regarding how to participate.The AGM is being held to: (i) receive the audited financial statements of the Company for its fiscal year ended December 31, 2025, and the report of the auditor thereon; (ii) fix the number of directors to be elected at eight; (iii) elect

SAN DIEGO, May 01, 2026 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (NASDAQ:ZNTL), a clinical oncology innovator advancing late-stage development of investigational first-in-class WEE1 inhibitor azenosertib as a biomarker-driven treatment approach for ovarian cancer, today announced that on May 1, 2026, the Compensation Committee of Zentalis' Board of Directors granted non-qualified stock options to purchase an aggregate of 26,000 shares of the Company's common stock to one (1) newly hired employee. The stock options were granted under the Zentalis Pharmaceuticals, Inc. 2022 Employment Inducement Incentive Award Plan (2022 Inducement Plan) as an inducement material to such individu

Jakafi XR is a once-daily, film-coated, extended-release formulation of Jakafi® (ruxolitinib) Once-daily Jakafi XR was shown to provide consistent, day-long exposure comparable to twice-daily Jakafi Jakafi XR will be available for pharmacy orders by May 8 Incyte (NASDAQ:INCY) today announced that the U.S. Food and Drug Administration (FDA) has approved Jakafi XR™ (ruxolitinib) extended-release tablets for the treatment of adults with intermediate- or high-risk myelofibrosis (MF); adults with polycythemia vera (PV) who have had an inadequate response to or are intolerant of hydroxyurea; as well as adults and children aged 12 years and older with steroid-refractory acute graft-versu

LANCASTER, Pa., May 1, 2026 /PRNewswire/ -- Fulton Financial Corporation (NASDAQ:FULT) ("Fulton") today announced the pricing of its underwritten public offering of $300 million aggregate principal amount of its Fixed-to-Floating Rate Subordinated Notes due 2036 (the "Notes"). The Notes will bear interest from and including May 5, 2026 to, but excluding, May 15, 2031, at a fixed rate of 5.950% per annum, payable semi-annually in arrears. From and including May 15, 2031 to, but excluding, May 15, 2036 (unless redeemed prior to such date), the Notes will bear interest at a floating rate per annum equal to the Three-Month Term SOFR, plus 217 basis points, payable quarterly in arrears.

Proposals to ICC would help to lower monthly customer bills in 2027 ComEd has initiated the annual reconciliation process, which matches actual costs of service with revenues. For 2025, ComEd is submitting two reconciliation filings with the Illinois Commerce Commission (ICC), which if approved would lead to a net decrease in charges on 2027 bills relative to this year's charges. The first, a revenue reconciliation filed March 20, compares revenues billed last year and the amount approved in ComEd's current Multi-year Rate Plan. That filing is expected to result in refunds for most residential customers. The second filing, a cost reconciliation submitted today, reflects a true-up of act

VANCOUVER, British Columbia, May 01, 2026 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology designed to optimize local, controlled drug delivery for applications with significant unmet need, today announced the appointment of Dr. Jeymi Tambiah as Chief Medical Officer (CMO) as well as the retirement of Dr. Mark Kowalski, Eupraxia's current CMO. Dr. Jeymi Tambiah (MB ChB, FRCS, MS, FAPCR, FFPM), is a Board Certified Cardiothoracic Surgeon physician scientist who practiced at Guys and St Thomas' Hospitals prior to entering the biopharmaceutical in

MINNEAPOLIS, May 01, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced positive topline results from the PIK3CA mutant cohort of the Phase 3 VIKTORIA-1 clinical trial evaluating gedatolisib plus fulvestrant with or without palbociclib in patients with hormone receptor positive ("HR+"), human epidermal growth factor receptor 2 negative ("HER2-"), PIK3CA mutant locally advanced or metastatic breast cancer ("ABC"), following progression on or after treatment with a CDK4/6 inhibitor and an aromatase inhibitor. Detailed results will be presented in a late-breaking abstract ("LBA")

Accendra Health, Inc. (NYSE:ACH) (the "Company") plans to release financial results for the first quarter of 2026 on Monday, May 11, 2026, before trading begins on the New York Stock Exchange. The Company will host a conference call for investors and analysts at 8:30 a.m. EDT on the same day. Participants may access the call via the toll-free dial-in number at 1-888-300-2035, or the toll dial-in number at 1-646-517-7437. The conference ID access code is 1058917. All interested stakeholders are encouraged to access the simultaneous live webcast by visiting the Investor Relations page of the Accendra Health website available at investors.accendra.com/events-and-presentations/. A replay of

PASCAGOULA, Miss., May 01, 2026 (GLOBE NEWSWIRE) -- HII's (NYSE:HII) Ingalls Shipbuilding division hosted its annual "Signing Day" today, recognizing 49 high school seniors from across the Gulf Coast who have completed the Ingalls Shipbuilder Academy (ISA) and accepted contingent employment offers with the company. Modeled after traditional athletic signings, the ceremony celebrates students as they formally commit to launching their careers in shipbuilding. "Through the Ingalls Shipbuilder Academy, we are developing the next generation of skilled shipbuilders," said Brian Blanchette, Ingalls Shipbuilding president. "Today we celebrate their first step toward meaningful, rewarding careers

SINGAPORE, May 01, 2026 (GLOBE NEWSWIRE) -- Trident Digital Tech Holdings Ltd (("Trident" or the "Company, NASDAQ:TDTH), a leading catalyst for digital transformation in technology optimization services and Web 3.0 activation based in Singapore, today announced that it received a letter dated April 28, 2026 from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") notifying the Company that since its listed securities did not have a closing bid price of at least US$1.00 for a minimum of 10 consecutive business days during the 180 calendar days ended April 27, 2026, the Company has not regained compliance with Nasdaq Listing Rule 5550(a)(2), which requires listed

FALLS CHURCH, Va., May 01, 2026 (GLOBE NEWSWIRE) -- Northrop Grumman Corporation (NYSE:NOC) continues to build on its spirit of innovation, honoring suppliers who are critical partners in advancing the defense industrial base for the U.S. and its allies. Northrop Grumman's Supplier Excellence Awards recognized over 30 domestic and global suppliers whose collaboration drives cutting-edge capabilities in autonomous systems, AI-driven analytics, advanced materials and secure cloud infrastructure, technologies essential for maintaining a decisive technological edge in today's contested global security environment. With four international businesses, 16 large businesses and 18 small businesses

DESIGNATED NEWS RELEASE VANCOUVER, BC, May 1, 2026 /CNW/ - Uranium Royalty Corp. (NASDAQ:UROY) (TSX:URC) ("URC" or the "Company") has closed its previously announced private placement of subscription receipts of the Company (the "Subscription Receipts") to Uranium Energy Corp. ("UEC") at a price of US$3.64 per Subscription Receipt, for aggregate gross of US$40 million. As disclosed in the Company's news release dated April 16, 2026, each Subscription Receipt will automatically convert into one common share in the capital of URC ("URC Shares") upon all escrow release conditions set out in the subscription agreement and the subscription receipt indenture being satisfied, including the conditio

OMAHA, Neb., May 01, 2026 (GLOBE NEWSWIRE) -- Exodus Movement, Inc. (NYSE:EXOD) ("Exodus"), a leading self-custodial cryptocurrency platform, today announced that it has acquired the outstanding shares of Monavate Holdings Limited, and Baanx.com Ltd., which were subsidiaries of W3C Corp ("W3C"), from the Receivers that were appointed in the United Kingdom to take control of these entities after W3C defaulted on a loan that was secured by these shares. The purchase price of these shares is $76.273.333.30, which is the exact amount of principal and interest outstanding on the W3C loan, as of April 30, 2026. Monavate Holdings Limited, together with its subsidiary Monavate Ltd and Baanx.com L

NOVAGOLD's Annual General Meeting of Shareholders will be held virtually on May 14, 2026, at 1:00 p.m. PDTShareholders may vote on matters before the Meeting by proxy, join the virtual Meeting and vote, and submit questions either during the webcast or in advance by emailFollowing the Meeting, Chairman Dr. Thomas S. Kaplan and President and CEO Greg Lang will discuss the strategic case for gold and NOVAGOLD's role within the broader investment thesis, building on Dr. Kaplan's extensive commentary on gold as a strategic asset. They will also highlight the latest catalysts for the Donlin Gold project — a long-life, federally permitted U.S. asset with scale and extraordinary leverage to gold.

MONTREAL, May 01, 2026 (GLOBE NEWSWIRE) -- CN (TSX:CNR) (NYSE:CNI) announced that the director nominees listed in the management information circular dated March 9, 2026 (the "Information Circular"), were elected as directors of CN. The detailed results of the vote for the election of directors held at CN's Annual Meeting of Shareholders ("Meeting") on May 1, 2026 via online webcast are set out below. Election of Directors On a vote by ballot, each of the following 11 nominees proposed by management was elected as a director of CN: NomineeVotes For % ForVotes Against % AgainstShauneen Bruder438,986,975 96.07%17,962,676 3.93%Jo-ann dePass Olsovsky430,546,313 94.22%26,403,335 5.78%David Fr

LA JOLLA, Calif., May 01, 2026 (GLOBE NEWSWIRE) -- Equillium, Inc. (NASDAQ:EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today announced that on May 1, 2026, the Compensation Committee of Equillium's Board of Directors granted inducement awards consisting of nonstatutory stock options to purchase an aggregate of 800,000 shares of common stock to two new employees under Equillium's 2024 Inducement Plan. The Compensation Committee approved the stock option grants as an inducement material to such employees' employment in accordance with Nasdaq Listing Rule 5635(c)(4). Each stock option has an exercise price per share equal t

SAN FRANCISCO, May 1, 2026 /PRNewswire/ -- Nektar Therapeutics (NASDAQ:NKTR) today announced that, on April 20, 2026, the Organization and Compensation Committee of Nektar's Board of Directors granted non-qualified stock options to purchase an aggregate of 28,450 shares of its common stock and 2,950 restricted stock units (RSUs) to six newly-hired employees under Nektar's 2025 Inducement Plan. Nektar's 2025 Inducement Plan was adopted by its Board of Directors on November 6, 2025 and is used exclusively for the grant of equity awards to individuals who were not previously an emp

The Annual and Special Meeting of Shareholders (the "Meeting") of RB Global, Inc. ((the ", Company", , TSX:RBA) was held on April 30, 2026. Each of the matters voted upon at the Meeting is discussed in detail in the Company's Proxy Statement dated March 19, 2026, which can be found on the Company's website at: https://s24.q4cdn.com/560830410/files/doc_financials/2026/ar/RB-Global-2026-Proxy-Statement-As-Filed-1.pdf. Per TSX reporting requirements, the Company wishes to disclose that the total number of shares represented by shareholders in person and by proxy at the Meeting was 162,807,309 common shares of the Company and 485,000,000 Series A senior preferred shares of the Company, repres